New Aspects of Melasma/Novi aspekti melazme

Open access


Melasma is a common cosmetic problem and its severity ranges from minor pigmentation during pregnancy that resolves spontaneously, to a chronic, troublesome, disfiguring condition. Today, there are various treatment modalities for melasma, providing a different success rate. The need for an effective treatment for melasma is becoming more and more significant probably due to the current lifestyles with increased UV exposure, broad use of hormones for contraception and hormone replacement therapy, as well as increasing esthetic demands. The mainstay of treatment is regular use of sunscreens along with topical medications suppressing melanogenesis. This review summarizes recent progress in understanding the pathophysiology of melasma and implications for new treatment strategies.

1. Rivas S, Pandya AG. Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol. 2013 Oct;14(5):359-76.

2. Ho SG, Chan HH. The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol. 2009;10(3):153-68.

3. Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013; 27(2):151-6.

4. Hexsel D, Lacerda DA, Cavalcante AS, Machado Filho CA, Kalil CL, Ayres EL, et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol. 2014;53(4):440-4.

5. Wu IB, Lambert C, Lotti TM, Hercogova J, Sintim-Damoa A, Schwartz RA. Melasma. G Ital Dermatol Venereol. 2012 Aug;147(4):413-8.

6. Kim NH, Lee CH, Lee AY. H19 RNA downregulation stimulated melanogenesis in melasma. Pigment Cell Melanoma Res. 2010 Feb;23(1):84-92.

7. Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol. 2000;1(5):261-8

8. Kim NH, Cheong KA, Lee TR, Lee AY. PDZK1 upregulation in estrogen-related hyperpigmentation in melasma. J Invest Dermatol. 2012 Nov;132(11):2622-31.

9. Lieberman R, Moy L. Estrogen receptor expression in melasma: results from facial skin of affected patients. J Drugs Dermatol. 2008 May;7(5):463-5.

10. Perez M, Sanchez JL, Aguilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 1983;81(6):543-5.

11. Sawhney M, Anand R. Chronic pelvic inflammatory disease and melasma in women. Indian J Dermatol Venereol Leprol. 2003;69(3):251-2.

12. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1254-62.

13. Bak H, Lee HJ, Chang SE, Choi JH, Kim MN, Kim BJ. Increased expression of nerve growth factor receptor and neural endopeptidase in the lesional skin of melasma. Dermatol Surg. 2009 Aug;35(8):1244-50.

14. Kim EJ, Park HY, Yaar M, Gilchrest BA. Modulation of vascular endothelial growth factor receptors in melanocytes. Exp Dermatol. 2005;14(8):625-33.

15. Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007;46(2):111-6.

16. Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim My, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32(5):626-33.

17. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27(2):96-101.

18. Katsambas A, Antoniou C. Melasma: classification and treatment. J Eur Acad Dermatol Venereol. 1995;4(3):217-23.

19. Gupta LK, Singhi MK. Wood’s lamp. Indian J Dermatol Venereol Leprol. 2004;70(2):131-5 .

20. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm Mc Jr. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981:4(6):698-710.

21. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011 Oct;65(4):689-97.

22. Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al . Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727-33.

23. Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. J Dermatolog Treat. 2007;18(1):5-9.

24. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida Ar, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006 Dec;156 Suppl 1:13-20.

25. Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutical approaches in melasma. Dermatol Clin. 2007 Jul;25(3):337-42.

26. Smit N, Vicanova J, Pavel S. The hunt for natural skin whitening agents. Int J Mol Sci. 2009 Dec 10;10(12):5326-49.

27. Katsambas AD, Stratigos AJ. Depigmenting and bleaching agents: coping with hyperpigmentation. Clin Dermatol. 2001 Jul-Aug;19(4):483-8.

28. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006 Dec;19(6):550-71.

29. Twenty-fourth directive 2000/6/EG Publication nr L 056, European Union; 2000.

30. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology - a potential health risk. J Cosmet Dermatol. 2005 Jun;4(2):55-9.

31. Enguita FJ, Leitao AL. Hydroquinone: environmental pollution, toxicity, and microbial answers. Biomed Res Int. 2013;2013:542168.

32. Gillner M, Moore GS, Cederberg H. International Programme on Chemical Safety Panel of Experts. Environmental Health Criteria 157: Hydroquinone. Available from: http://www.

33. U.S. Food & Drug Administration, Department of Health and Human Services. Nomination Profile: Hydroquinone [CAS 123-31-9]. Supporting Information for Toxicological Evaluation by the National Toxicology Program 21 May 2009. Available from: docs/hydroquinone_may2009.pdf

34. Katsambas AD, Stratigos AJ, Lotti TM. Melasma. In: Katsambas AD, Lotti TM, editors. European handbook of dermatological treatments. 2nd ed. Berlin: Springer; 2003. p. 336-41.

35. Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol. 2011 Dec;10(4):282-7.

36. Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK. A Comparative study of the efficacy of 4% hydroquinone vs 0.75% Kojic acid cream in the treatment of facial melasma. Indian J Dermatol. 2013 Mar;58(2):157.

37. Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic acid vis-a-vis its combinations with hydroquinone and betamethasone valerate in melasma: a randomized, single blind, comparative study of efficacy and safety. Indian J Dermatol. 2013 Jul;58(4):281-5.

38. Taylor MB, Yanaki JS, Draper DO, Shurtz JC, Coglianese M. Successful short-term and long-term treatment of melasma and postinflammatory hyperpigmentation using vitamin C with a full-face iontophoresis mask and a mandelic/malic acid skin care regimen. J Drugs Dermatol. 2013 Jan;12(1):45-50.

39. Ortonne JP. Retinoid therapy of pigmentary disorders. Dermatol Ther. 2006 Sep-Oct;19(5):280-8

40. Gold M, Rendon M, Dibernardo B, Bruce S, Lucas-Anthony C, Watson J. Open-label treatment of moderate or marked melasma with a 4% hydroquinone skin care system plus 0.05% tretinoin cream. J Clin Aesthet Dermatol. 2013 Nov;6(11):32-8.

41. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol. 2002 Aug;29(8):539-40.

42. Faghihi G, Shahingohar A, Siadat AH. Comparison between 1% tretinoin peeling versus 70% glycolic acid peeling in the treatment of female patients with melasma. J Drugs Dermatol. 2011 Dec;10(12):1439-42.

43. Brazzini B, Hautmann G, Ghersetich I, Hercogova J, Lotti T. Laser tissue interaction in epidermal pigmented lesions. J Eur Acad Dermatol Venereol. 2001 Sep;15(5):388-91.

44. Lee DB, Suh HS, Choi YS. A comparative study of lowfluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner’s solution in melasma patients. J Dermatolog Treat. 2014 Dec;25(6):523-8.

45. Lee HI, Lim YY, Kim BJ, Kim MN, Min HJ, Hwang JH, et al. Clinicopathologic efficacy of copper bromide plus/yellow laser (578 nm with 511 nm) for treatment of melasma in Asian patients. Dermatol Surg. 2010 Jun;36(6):885-93.

46. Zaleski L, Fabi S, Goldman MP. Treatment of melasma and the use of intense pulsed light: a review. J Drugs Dermatol. 2012 Nov;11(11):1316-20.

47. Figueiredo Souza L, Trancoso Souza S. Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma. Dermatol Ther. 2012 Sep-Oct;25(5):477-80.

48. Chung JY, Choi M, Lee JH, Cho S, Lee JH. Pulse in pulse intense pulsed light for melasma treatment: a pilot study. Dermatol Surg. 2014 Feb;40(2):162-8.

49. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006 May;54(5 Suppl 2):S272-81.

50. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007 Sep-Oct;20(5):308-13.

51. Yousefi A, Khani Khoozani Z, Zakerzadeh Forooshani S, Omrani N, Moini AM, Eskandari Y. Is topical zinc effective in the treatment of melasma? A double-blind randomized comparative study. Dermatol Surg. 2014 Jan;40(1):33-7.

52. Zhu W, Gao J. The use of botanical extracts as topical skinlightening agents for the improvement of skin pigmentation disorders. J Investig Dermatol Symp Proc. 2008 Apr;13(1):20-4.

Serbian Journal of Dermatology and Venereology

The Journal of Serbian Association of Dermatovenereologists (SAD)

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 160 160 21
PDF Downloads 60 60 11